FDA accelerated approval benefits glioblastoma.

摘要

Recurrent glioblastoma is a fatal disease with no clear standard of care. In the past 20 years, the neuro-oncology academic community has done many well-designed, well-conducted trials using various systemic agents. The use of uniform inclusion and exclusion criteria in multicentre trials, and centralised discipline reviews, provide reproducible outcomes-response rates of less than 10%, 6-month progression-free survival of 20% or less, and overall survival ranging from 5 to 7 months.